• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Siegfried acquires Alliance Medical Products

Siegfried acquires Alliance Medical Products

June 7, 2012
CenterWatch Staff

Switzerland-based Siegfried Holding has acquired Alliance Medical Products (AMP), a full service FDA, MHRA and ISO13485 certified CMO, of Irvine, Calif, giving Siegfried an entry into the custom market for sterile filling services.

The purchase consists of a cash payment in the amount of $58 million and contingent earn-out consideration subject to AMP meeting defined profitability goals for the fiscal year ending December 31, 2013. The transaction is expected to be accretive already in 2012.

The addition of sterile filling capabilities has been a strategic goal of the Siegfried Group and will advance its technology base. The acquisition represents an important step toward additional profitable growth for Siegfried.

"Siegfried is one of the few companies with capabilities in both pharmaceutical and chemical manufacturing,” said Dr. Rudolf Hanko, CEO of Siegfried. “Our acquisition of AMP expands our exceptional CMO platform into the sterile filling market, a particularly attractive segment.”

In 2011, AMP achieved revenues of $20 million with approximately 100 employees. The company operates profitably, has an attractive client base and a substantial project pipeline. It is expected to continue its growth and provide a strong contribution to the equity value of the Siegfried. To ensure a seamless integration, the management of AMP will remain in place.

"Our association with Siegfried opens exciting growth and expansion possibilities for AMP,” added Juan Valdes, CEO of AMP. “The combination of sterile filling services with the production of active pharmaceutical ingredients is unique in the custom manufacturing market."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing